METHODS: A clinical trial was conducted involving 80 stage I-III active-treatment breast cancer patients with a score greater than 34 on the Fear of Progression Questionnaire-Short Form scale. These patients were randomly assigned in a 1:1 ratio to either an intervention group, which received weekly 70-min sessions of 5-ACT-bsed group-therapy, or a control group that received usual treatment. Variables including FOP, AS, QOL, and ACT-related factors were assessed using ASQ, QLQ-C30, Cognitive Fusion Questionnaire, and Acceptance and Action Questionnaire-II at three time points: baseline, post-intervention, and 3-month follow-up. The efficacy of the intervention was evaluated using mixed model analysis across all time-points.
RESULTS: The fidelity and acceptability of the ACT-based manual were confirmed using significant methods. A significant reduction in FOP was observed only in the ACT group at post-intervention (P-valueACT < 0.001; Cohen dACT = 1.099). Furthermore, the ACT group demonstrated a more significant reduction in FOP at follow-up. Furthermore, all secondary and ACT-related variables, except for the physical symptoms subscale, showed significant improvement in the ACT group compared to the control group.
CONCLUSIONS: Our ACT-based manual showed promise for reducing FOP, AS, and improving QOL, and ACT-related variables in breast cancer patients 3 months following the intervention.
方法:进行了一项临床试验,涉及80名I-III期积极治疗的乳腺癌患者,其在恐惧进展问卷-简短形式量表上得分大于34分。这些患者以1:1的比例随机分配到干预组,每周接受70分钟的5-ACT-bsed组治疗,或接受常规治疗的对照组。变量包括FOP,AS,QOL,使用ASQ评估ACT相关因素,QLQ-C30,认知融合问卷,以及三个时间点的接受和行动问卷-II:基线,干预后,和3个月的随访。在所有时间点使用混合模型分析评估干预的有效性。
结果:使用有意义的方法确认了基于ACT的手册的保真度和可接受性。干预后,仅在ACT组中观察到FOP的显着降低(P值ACT<0.001;CohendACT=1.099)。此外,ACT组随访时FOP的减少更为显著.此外,所有次要和ACT相关变量,除了身体症状分量表,与对照组相比,ACT组显着改善。
结论:我们基于ACT的手册显示出减少FOP的希望,AS,提高生活质量,干预后3个月,乳腺癌患者的ACT相关变量。